Results 11 to 20 of about 24,117 (172)
Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. [PDF]
PLoS ONE, 2012 BackgroundAgitation in Alzheimer's disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased morbidity and ...
Chris Fox +9 more
doaj +3 more sources
Pharmacokinetic Drug-Drug Interaction and Responsible Mechanism between Memantine and Cimetidine
Pharmaceutics, 2018 A sensitive and simple chromatography-tandem mass spectrometry (LC-MS/MS) method was developed to evaluate memantine in rat plasma. Memantine and propranolol (internal standard) in rat plasma was extracted using a methanol precipitation method.
Young A. Choi +2 more
doaj +2 more sources
Memantine has no effect on KATP channels in pancreatic β cells
BMC Research Notes, 2018 Objective Memantine, a drug for Alzheimer’s disease, is considered to suppress excessive stimulation of N-methyl-d-aspartic acid receptors and to prevent neuronal death.
Ryota Imai +6 more
doaj +2 more sources
Bioequivalence study drug containing memantine [PDF]
Фармакокинетика и Фармакодинамика, 2013 At present, Russia has developed domestic analogue of Memantine Akatinol — Memaneyrin in the form of droplets which is pharmaceutically equivalent drug memantine Akatinol.
A. A. Karlitskaya +5 more
doaj +1 more source
Memantine as an Augmentation Therapy for Anxiety Disorders
Case Reports in Psychiatry, 2012 Objective. Glutamate, an excitatory neurotransmitter in the central nervous system (CNS), may play a role in the development of anxiety. Memantine partially blocks N-methyl-D-aspartate (NMDA) receptors' glutamate channels located in the CNS.
Thomas L. Schwartz +2 more
doaj +2 more sources
Neuropsychiatric Disease and Treatment, 2018 Taro Kishi,1,* Shinji Matsunaga,1,2,* Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan; 2Department of Geriatrics and Cognitive Disorders, Fujita Health University School of Medicine ...
Kishi T, Matsunaga S, Iwata N
doaj +1 more source
Update on the use of memantine in Alzheimer’s disease
Neuropsychiatric Disease and Treatment, 2009 Robert J van MarumGeriatric Department, University Medical Center Utrecht, Utrecht, The NetherlandsAbstract: Memantine is a low to moderate affinity N-methyl-D-aspartate receptor (NMDAR) antagonist.
Robert J van Marum
doaj +1 more source
Clinical Interventions in Aging, 2009 Stuart J Thomas, George T GrossbergDepartment of Neurology and Psychiatry, Saint Louis University School of Medicine, St. Louis, MO, USAAbstract: Memantine is an uncompetitive N-methyl-D-aspartate receptor antagonist with moderate affinity. Its mechanism
Stuart J Thomas, George T Grossberg
doaj +1 more source
Memantine for the treatment of frontotemporal dementia: a meta-analysis
Neuropsychiatric Disease and Treatment, 2015 Taro Kishi, Shinji Matsunaga, Nakao Iwata Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan Background: There is no conclusive evidence supporting the efficacy of memantine in frontotemporal dementia (FTD).
Kishi T, Matsunaga S, Iwata N
doaj +1 more source
Neuropsychiatric Disease and Treatment, 2017 Taro Kishi,* Shinji Matsunaga,* Nakao Iwata Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan *These authors contributed equally to this work Background: Memantine is effective in the treatment of behavioral ...
Kishi T, Matsunaga S, Iwata N
doaj +1 more source